Posted by Michael Wonder on 20 Dec 2022
ICER provides update on value based pricing of Paxlovid as an outpatient treatment for COVID-19
20 December 2022 - New data suggests Paxlovid will achieve common thresholds of cost effectiveness if priced between $563-$906 per treatment course.
Based on a review of new data since our initial assessment in May 2022, the ICER today posted an update to the health benefit price benchmark for nirmatrelvir and ritonavir (Paxlovid, Pfizer) for the treatment of COVID-19.
